{
  "drugid": "RxNorm:36437",
  "drugname": "sertraline",
  "guidelinename": "CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/",
  "guidelinepharmgkbids": [],
  "citations": [
    {
      "pmid": "37032427",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.",
      "authors": [
        "Bousman Chad A",
        "Stevenson James M",
        "Ramsey Laura B",
        "Sangkuhl Katrin",
        "Hicks J Kevin",
        "Strawn Jeffrey R",
        "Singh Ajeet B",
        "Rua√±o Gualberto",
        "Mueller Daniel J",
        "Tsermpini Evangelia Eirini",
        "Brown Jacob T",
        "Bell Gillian C",
        "Leeder J Steven",
        "Gaedigk Andrea",
        "Scott Stuart A",
        "Klein Teri E",
        "Caudle Kelly E",
        "Bishop Jeffrey R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2023
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "comments": "CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Indeterminate"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "No Result"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "No Result"
      },
      "comments": "CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "No Result"
      },
      "comments": "CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Intermediate Metabolizer",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher\nmaintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Ultrarapid Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.",
        "CYP2C19": "Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Poor Metabolizer",
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "No Result",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "No Result",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "No Result"
      },
      "comments": "CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.",
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Rapid Metabolizer",
        "CYP2C19": "No Result"
      },
      "comments": "CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "n/a",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Indeterminate",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2B6": "Normal metabolism of sertraline to less active compounds.",
        "CYP2C19": "Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2B6": "n/a",
        "CYP2C19": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2B6": "Normal Metabolizer",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2B6",
    "CYP2C19"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.30.0",
  "source": "CPIC"
}